Latest Insider Transactions at Adicet Bio, Inc. (ACET)
This section provides a real-time view of insider transactions for Adicet Bio, Inc. (ACET). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adicet Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adicet Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 28
2022
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,288
-14.78%
|
$234,168
$11.69 P/Share
|
|
Jan 28
2022
|
Chen Schor President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,000
+25.0%
|
-
|
|
Jan 28
2022
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,696
-9.78%
|
$51,656
$11.69 P/Share
|
|
Jan 28
2022
|
Brian Nicholas Harvey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.0%
|
-
|
|
Jan 28
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,564
-11.59%
|
$61,204
$11.69 P/Share
|
|
Jan 28
2022
|
Blake Aftab Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.0%
|
-
|
|
Jan 28
2022
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-11.53%
|
$60,863
$11.69 P/Share
|
|
Jan 28
2022
|
Don Healey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.0%
|
-
|
|
Jan 28
2022
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-10.06%
|
$60,863
$11.69 P/Share
|
|
Jan 28
2022
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+22.54%
|
-
|
|
Jan 05
2022
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
4,000
-0.55%
|
$64,000
$16.92 P/Share
|
|
Jan 03
2022
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
12,000
-1.61%
|
$216,000
$18.02 P/Share
|
|
Dec 10
2021
|
Carl L Gordon |
BUY
Grant, award, or other acquisition
|
Indirect |
214,285
+46.93%
|
$2,999,990
$14.0 P/Share
|
|
Dec 10
2021
|
Orbimed Advisors LLC |
BUY
Grant, award, or other acquisition
|
Indirect |
214,285
+46.93%
|
$2,999,990
$14.0 P/Share
|
|
Dec 08
2021
|
Andrew Sinclair |
BUY
Open market or private purchase
|
Indirect |
500,000
+18.93%
|
$7,000,000
$14.0 P/Share
|
|
Oct 12
2021
|
Blake Aftab Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+50.0%
|
-
|
|
Oct 01
2021
|
Brian Nicholas Harvey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+50.0%
|
-
|
|
Oct 01
2021
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+47.91%
|
-
|
|
Oct 01
2021
|
Don Healey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+50.0%
|
-
|
|
Oct 01
2021
|
Chen Schor President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
240,000
+50.0%
|
-
|
|
Jun 16
2021
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
16,466
-9.09%
|
$164,660
$10.53 P/Share
|
|
Jun 15
2021
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
3,847
-0.88%
|
$42,317
$11.16 P/Share
|
|
Jun 04
2021
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,983
+50.0%
|
$34,915
$5.97 P/Share
|
|
Jun 03
2021
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
16,466
-8.33%
|
$197,592
$12.06 P/Share
|
|
May 20
2021
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
1,792
-0.41%
|
$25,088
$14.23 P/Share
|
|
May 19
2021
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
16,466
-3.87%
|
$214,058
$13.58 P/Share
|
|
May 18
2021
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
6,208
-1.4%
|
$86,912
$14.06 P/Share
|
|
May 12
2021
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
10,000
-2.2%
|
$130,000
$13.24 P/Share
|
|
May 05
2021
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
16,466
-3.64%
|
$230,524
$14.3 P/Share
|
|
Apr 20
2021
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
16,466
-6.67%
|
$197,592
$12.01 P/Share
|
|
Apr 06
2021
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
16,466
-6.25%
|
$214,058
$13.04 P/Share
|
|
Mar 30
2021
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
16,466
-2.98%
|
$197,592
$12.76 P/Share
|
|
Mar 16
2021
|
Chen Schor President & CEO |
SELL
Open market or private sale
|
Indirect |
16,466
-2.81%
|
$246,990
$15.37 P/Share
|
|
Feb 12
2021
|
Carl L Gordon |
BUY
Grant, award, or other acquisition
|
Indirect |
524,349
+14.1%
|
$6,816,537
$13.0 P/Share
|
|
Feb 12
2021
|
Erez Chimovits Director |
BUY
Grant, award, or other acquisition
|
Indirect |
524,349
+14.1%
|
$6,816,537
$13.0 P/Share
|
|
Feb 12
2021
|
Orbimed Advisors LLC |
BUY
Grant, award, or other acquisition
|
Indirect |
524,349
+14.1%
|
$6,816,537
$13.0 P/Share
|
|
Oct 23
2020
|
Lloyd Klickstein |
SELL
Payment of exercise price or tax liability
|
Direct |
4,957
-29.35%
|
-
|
|
Oct 23
2020
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,649
-10.66%
|
-
|
|
Sep 15
2020
|
Orbimed Advisors LLC |
BUY
Grant, award, or other acquisition
|
Indirect |
6,018,452
+50.0%
|
-
|
|
Dec 06
2019
|
Lloyd Klickstein |
SELL
Grant, award, or other acquisition
|
Direct |
16,888
-50.0%
|
-
|
|
Jan 30
2018
|
Orbimed Advisors LLC |
BUY
Open market or private purchase
|
Indirect |
533,333
+9.94%
|
$7,999,995
$15.0 P/Share
|
|
Jan 30
2018
|
Orbimed Advisors LLC |
BUY
Conversion of derivative security
|
Indirect |
4,297,054
+40.17%
|
-
|